Home > News > Headline News > Archive

Click on title to read the full article.

Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer

July 22, 2009

By Medical News Today

WAYNE, N.J. and EMERYVILLE, Calif., — Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today announced that their first cooperative group-sponsored randomized Phase 2 trial in advanced metastatic breast cancer met its primary endpoint of progression-free survival. The study evaluated Nexavar(R) (sorafenib) tablets in combination with the oral chemotherapeutic, capecitabine, in patients with locally advanced or metastatic HER-2 negative breast cancer.

Denosumab More Effective than Zometa® in Patients with Bone Metastases

July 18, 2009

By Cancer Consultants

Among women with bone metastases from breast cancer, the investigational drug denosumab was more effective than Zometa® (zoledronic acid) at reducing the risk of bone complications such as fracture. The results of this Phase III clinical trial were made available in a press release from Amgen.

Abraxane Beats Standard Breast Cancer Treatment

July 17, 2009

By Charlene Laino, WebMD

For women with breast cancer that has spread to other parts of the body, the chemotherapy drug Abraxane works better, and with fewer side effects, than the standard drug treatment, a new study suggests.

Significantly Longer Progression-Free Survival With nab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic

July 17, 2009

By William Gradishar, Northwestern University Feinberg School of Medicine

Purpose: In patients with metastatic breast cancer (MBC), nab-paclitaxel produced significantly higher antitumor activity compared with patients who received solvent-based paclitaxel. This phase II study examined the antitumor activity and safety of weekly and every 3 week (q3w) nab-paclitaxel compared with docetaxel as first-line treatment in patients with MBC.